These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11406248)

  • 1. A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine.
    Corpataux JM; Munafo A; Buclin T; Biollaz J; Mosimann F
    Transplant Proc; 2001 Jun; 33(4):2557-62. PubMed ID: 11406248
    [No Abstract]   [Full Text] [Related]  

  • 2. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
    Muñoz AE; Miguez C; Rubio M; Bartellini M; Levi D; Podestá A; Niselman V; Terg R
    Dig Dis Sci; 1999 Apr; 44(4):789-95. PubMed ID: 10219840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral or intravenous lidocaine administration to perform megx test?
    Giannini E; Botta F; Romagnoli P; Testa R
    Dig Dis Sci; 2000 May; 45(5):1011-2. PubMed ID: 10795769
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of lidocaine and its active metabolite monoethylglycinexylidide after a single intravenous administration in chickens (Gallus domesticus) anesthetized with isoflurane.
    Da Cunha AF; Messenger KM; Stout RW; Barker SA; Nevarez JG; Queiroz-Williams P; Tully TN
    J Vet Pharmacol Ther; 2012 Dec; 35(6):604-7. PubMed ID: 22212047
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.
    Oellerich M; Raude E; Burdelski M; Schulz M; Schmidt FW; Ringe B; Lamesch P; Pichlmayr R; Raith H; Scheruhn M
    J Clin Chem Clin Biochem; 1987 Dec; 25(12):845-53. PubMed ID: 3443824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.
    Wojcicki J; Kozlowski K; Drozdzik M; Wojcicki M
    Eur J Drug Metab Pharmacokinet; 2002; 27(4):243-7. PubMed ID: 12587953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lidocaine elimination in patients with liver cirrhosis.
    Wójcicki J; Kozłowski K; Droździk M; Wójcicki M
    Acta Pol Pharm; 2002; 59(4):321-4. PubMed ID: 12403308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.
    Fasoli A; Giannini E; Botta F; Romagnoli P; Risso D; Celle G; Testa R
    Hepatogastroenterology; 2000; 47(31):234-8. PubMed ID: 10690614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects.
    Reichel C; Nacke A; Sudhop T; Wienkoop G; Lüers C; Hahn C; Pohl C; Spengler U; Sauerbruch T
    Hepatology; 1997 Jun; 25(6):1323-7. PubMed ID: 9185746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoethylglycinexylidide production as a measure in predicting hepatic histology.
    Forte G; Rocco P; Costanzo A; Grimaldi E; Rossi R; Bottiglieri ME; Biceglia O; Zampella G
    Ital J Gastroenterol; 1994 May; 26(4):159-62. PubMed ID: 7949258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
    Testa R; Borzone S; Campo N; Alvarez S; Caglieris S; Arzani L; Risso D; Lantieri PB; Celle G
    Transplant Proc; 1994 Dec; 26(6):3624-5. PubMed ID: 7998297
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion.
    Estes NA; Manolis AS; Greenblatt DJ; Garan H; Ruskin JN
    Am Heart J; 1989 May; 117(5):1060-4. PubMed ID: 2711965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
    Isohanni MH; Neuvonen PJ; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function].
    Klinker H; Joeres R; Bomhard M; Keller F; Dorer J; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():52-5. PubMed ID: 7483715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.
    Testa R; Caglieris S; Risso D; Arzani L; Campo N; Alvarez S; Giannini E; Lantieri PB; Celle G
    Am J Gastroenterol; 1997 Dec; 92(12):2268-73. PubMed ID: 9399768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis.
    Testa R; Campo N; Caglieris S; Risso D; Alvarez S; Arzani L; Giannini E; Lantieri PB; Celle G
    Hepatogastroenterology; 1998; 45(19):154-9. PubMed ID: 9496506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse.
    Soma LR; You Y; Robinson MA; Boston RC
    J Vet Pharmacol Ther; 2018 Dec; 41(6):825-837. PubMed ID: 30028024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].
    Kupcová V; Turecký L; Szántová M; Schmidtová K
    Bratisl Lek Listy; 1999 Jan; 100(1):12-24. PubMed ID: 10492993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of liver disease and food on plasma MEGX concentrations.
    Pritchard-Davies R; Gross AS; Shenfield GM
    Br J Clin Pharmacol; 1994 Mar; 37(3):298-301. PubMed ID: 8198941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of hyperlipidemia on metabolism, distribution and secretion of lidocaine in patients with primary hyperlipidemia].
    Rózański J
    Ann Acad Med Stetin; 2000; 46():177-87. PubMed ID: 11712303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.